The investigation is focused on whether AstraZeneca employees were complicit in importing an unlicensed liver cancer drug into mainland China, raising serious ethical concerns over patient safety.
AstraZeneca acknowledged that a small number of its employees in China are under investigation, but did not provide further details on the ongoing matters or implications of the detentions.
In the context of a broad anti-corruption effort by Beijing, this investigation reflects increasing scrutiny within the pharmaceutical industry regarding data privacy and ethical marketing practices.
With China representing a significant portion of AstraZeneca's revenue—approximately 13%—the company's potential reevaluation of its China operations highlights the challenges faced in navigating regulatory landscapes.
Collection
[
|
...
]